Fluoroquinolone levels in healthy dog urine following a 20‐mg/kg oral dose of enrofloxacin exceed mutant prevention concentration targets against Escherichia coli isolated from canine urinary tract infections

A 3‐day course of oral enrofloxacin is effective for treating uncomplicated urinary tract infection (UTI) in dogs when administered 20 mg/kg Q24H. However, emergence of fluoroquinolone‐resistant mutants of uropathogens is a concern. Urine concentrations of enrofloxacin and ciprofloxacin were measure...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary pharmacology and therapeutics 2014-04, Vol.37 (2), p.201-204
Main Authors: Daniels, J. B, Tracy, G, Irom, S. J, Lakritz, J
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - urine
bladder
ciprofloxacin
Ciprofloxacin - metabolism
Ciprofloxacin - urine
Dog Diseases - microbiology
dogs
Dogs - urine
Drug Resistance, Bacterial
enrofloxacin
Escherichia coli
Escherichia coli - drug effects
Escherichia coli Infections - veterinary
Fluoroquinolones - metabolism
Fluoroquinolones - pharmacokinetics
Fluoroquinolones - urine
Mutation
Urinary Tract Infections - microbiology
Urinary Tract Infections - veterinary
urine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 3‐day course of oral enrofloxacin is effective for treating uncomplicated urinary tract infection (UTI) in dogs when administered 20 mg/kg Q24H. However, emergence of fluoroquinolone‐resistant mutants of uropathogens is a concern. Urine concentrations of enrofloxacin and ciprofloxacin were measured in six healthy dogs following dose of enrofloxacin 20 mg/kg. Mutant prevention concentrations of Escherichia coli isolated from canine UTI were also determined against ciprofloxacin. Urine AUC(24)/MPC ratios considering ciprofloxacin concentrations ranged 3819–7767, indicating that selection of resistant E. coli mutants in dogs with uncomplicated UTIs is unlikely in the bladder given that an AUC(24)/MPC = 39 is considered to be protective against mutant selection for ciprofloxacin. However, additional studies are required to evaluate the effects of this enrofloxacin treatment protocol on bacteria that colonize anatomic sites where fluoroquinolones achieve lower concentrations compared to the urinary bladder.
ISSN:0140-7783
1365-2885
DOI:10.1111/jvp.12069